| Literature DB >> 1405609 |
T P Wade1, A Kasid, C A Stein, R V LaRocca, E R Sargent, L G Gomella, C E Myers, W M Linehan.
Abstract
Suramin is a polyanionic compound used clinically for the treatment of trypanosomiasis, which is known to inhibit the action of many protein factors in vitro. Transforming growth factor-beta (TGF-beta) is a multifunctional regulatory protein which inhibits the growth of renal cell carcinoma in culture. While suramin at 50-500 micrograms/ml had no significant effect on the growth of renal cell carcinoma in culture in our experiments, it did partially reverse the growth inhibition induced by TGF-beta in the two cell lines tested. This effect apparently is caused by suramin's direct interference with 125I-labeled TGF-beta's ability to bind to the cell, and not by any effect of suramin on the TGF-beta receptor. Furthermore, suramin dissociates TGF-beta bound to the cell with a t1/2 of less than 30 min. These results are consistent with those previously reported regarding suramin's interaction with other protein growth factors, and suggest that suramin may interact with the TGF-beta protein itself to inactivate it.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1405609 DOI： 10.1016/0022-4804(92)90034-w
Source DB: PubMed Journal: J Surg Res ISSN： 0022-4804 Impact factor: 2.192